Jones Financial Companies Lllp boosted its position in shares of Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report) by 83.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 98,250 shares of the company’s stock after purchasing an additional 44,750 shares during the quarter. Jones Financial Companies Lllp owned about 0.37% of Gain Therapeutics worth $212,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sprott Inc. acquired a new position in shares of Gain Therapeutics during the 4th quarter worth about $30,000. Benedict Financial Advisors Inc. acquired a new position in shares of Gain Therapeutics during the 4th quarter worth about $35,000. Finally, Geode Capital Management LLC grew its position in shares of Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after buying an additional 88,236 shares during the period. 11.97% of the stock is owned by institutional investors.
Gain Therapeutics Price Performance
Shares of GANX opened at $2.20 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The stock has a 50 day simple moving average of $2.23 and a 200 day simple moving average of $1.97. Gain Therapeutics, Inc. has a 52-week low of $0.89 and a 52-week high of $4.63. The firm has a market capitalization of $58.36 million, a PE ratio of -2.00 and a beta of 0.14.
Wall Street Analyst Weigh In
Check Out Our Latest Report on GANX
About Gain Therapeutics
Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Read More
- Five stocks we like better than Gain Therapeutics
- Top Biotech Stocks: Exploring Innovation Opportunities
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Learn Technical Analysis Skills to Master the Stock Market
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- Best Stocks Under $5.00
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Want to see what other hedge funds are holding GANX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gain Therapeutics, Inc. (NASDAQ:GANX – Free Report).
Receive News & Ratings for Gain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.